Thromboembolic stroke in patients with a HeartMate-II left ventricular assist device – the role of anticoagulation

Journal of Cardiothoracic Surgery

Arjen JC Slooter²  Jaap R. Lahpor³  Annemarie E. Engström⁴  Abram L. van Duijn²  Annemieke Oude Lansink-Hartgring¹  Walter M. van den Bergh³ 

[1] Department of Critical Care, UMC Groningen, University of Groningen, Groningen 9700 RB, The Netherlands;Department of Intensive Care, UMC Utrecht, Utrecht, The Netherlands;Department of Cardiology, AMC, University of Amsterdam, Amsterdam, The Netherlands;Department of Cardiothoracic Surgery, UMC Utrecht, Utrecht, The Netherlands

关键词: Platelet aggregation inhibitors;    Coumarins;    Anticoagulants;    Stroke;    Heart-assist devices;   

Others  :  1230552
DOI  :  10.1186/s13019-015-0333-7

 received in 2015-01-14, accepted in 2015-10-05,  发布年份 2015

【 摘 要 】

Background and purpose

It is unknown what the optimal anticoagulant level is to prevent thromboembolic stroke in patients with left ventricular assist device (LVAD) support. We aimed to evaluate the relation between coagulation status and the occurrence of thromboembolic stroke in HeartMate-II LVAD assisted patients.

Methods

Thirty-eight consecutive patients with a HeartMate-II LVAD were included. Coagulation status was classified according to INR and aPTT ratio at: 1) the moment of first thromboembolic stroke; and 2) during the two weeks preceding the first thromboembolic stroke to assess long-term coagulation status. In patients without stroke, coagulation status was determined just before heart transplant, VAD explantation or death, whichever came first, and at two weeks preceding these surrogate endpoints. Based on coagulation status, patients were divided in two groups: Group I (reference group) was defined as INR below 2 and aPTT ratio below 1.5; Group II (adequate anticoagulation) as INR above 2 or aPTT ratio above 1.5. Logistic regression analysis was performed to assess the odds ratio for developing stroke for patients with adequate anticoagulation compared to the reference Group.

Results

Thromboembolic stroke occurred in six (16 %) patients, none within 2 weeks after LVAD implantation. Considering coagulation status at the time of event, patients in coagulation Group II had no decreased risk for thromboembolic stroke (OR 0.78; 95 % CI 0.12–5.0). Results for coagulation status 2 weeks prior of event could not be calculated as all six strokes occurred in Group II.

Conclusion

In our experience anticoagulation within predefined targets is not associated with a reduced thromboembolic stroke risk in patients with a HeartMate-II LVAD on antiplatelet therapy. However, no firm statement about the effect of either anticoagulant or antiaggregant therapy can be made based on our study. A larger randomized study is needed to support the hypothesis that there may be no additional benefit of coumarin or heparin therapy compared with antiplatelet therapy alone.

【 授权许可】

   
2015 van den Bergh et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B et al.. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001; 122(6):1186-1195.
• [2]Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA et al.. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010; 29(1):1-10.
• [3]Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W et al.. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345(20):1435-1443.
• [4]Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D et al.. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23):2241-2251.
• [5]John R, Kamdar F, Liao K, Colvin-Adams M, Miller L, Joyce L et al.. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008; 136(5):1318-1323.
• [6]Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD et al.. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009; 28(9):881-887.
• [7]Schmid C, Weyand M, Nabavi DG, Hammel D, Deng MC, Ringelstein EB et al.. Cerebral and systemic embolization during left ventricular support with the Novacor N100 device. Ann Thorac Surg. 1998; 65(6):1703-1710.
• [8]Slater JP, Rose EA, Levin HR, Frazier OH, Roberts JK, Weinberg AD et al.. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg. 1996; 62(5):1321-1327.
• [9]Crow S, Chen D, Milano C, Thomas W, Joyce L, Piacentino V et al.. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010; 90(4):1263-1269.
• [10]Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A et al.. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010; 56(15):1207-1213.
• [11]Nakajima I, Kato TS, Komamura K, Takahashi A, Oda N, Sasaoka T et al.. Pre- and post-operative risk factors associated with cerebrovascular accidents in patients supported by left ventricular assist device. -Single center's experience in Japan-. Circ J. 2011; 75(5):1138-1146.
• [12]Whitson BA, Eckman P, Kamdar F, Lacey A, Shumway SJ, Liao KK et al.. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg. 2014; 97(6):2097-2103.
• [13]Morgan JA, Brewer RJ, Nemeh HW, Gerlach B, Lanfear DE, Williams CT et al.. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014; 60(3):284-289.
• [14]Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg. 2012; 42(2):319-323.
• [15]Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995; 142(12):1255-1264.
• [16]Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-387.
• [17]Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006; 59(10):1087-1091.
• [18]Koene RJ, Win S, Naksuk N, Adatya SN, Rosenbaum AN, John R et al.. HAS-BLED and CHA 2 DS 2 -VASc scores as predictors of bleeding and thrombotic risk after continuous-flow ventricular assist device implantation. J Card Fail. 2014; 20(11):800-807.
• [19]Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C et al.. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706):1967-1974.
• [20]Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012; 42(4):612-620.
• [21]Critoph C, Chih S, Baumwol J. The World's Longest-Supported HeartWare Ventricular Assist Device Patient: 6 Years and Counting on Minimal Anticoagulation. Artif Organs. 2014; 38(5):434-435.
• [22]Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA et al.. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014; 370(1):33-40.
• [23]Bluestein D, Girdhar G, Einav S, Slepian MJ. Device thrombogenicity emulation: a novel methodology for optimizing the thromboresistance of cardiovascular devices. J Biomech. 2013; 46(2):338-344.